Catherine Drai,Hanneke J van der Woude,Anne J Lexmond,Tineke van den Hoorn,Peter G M Mol,Finbarr P Leacy,Agnieszka Przybyszewska,Bruno Sepodes,Thomas Castelnovo
{"title":"欧洲药品管理局(ema)对Kaftrio (elexacaftor-tezacaftor-ivacaftor)的审查:将其应用范围扩大到所有2岁及以上且没有两种I类CFTR变体的CF患者。","authors":"Catherine Drai,Hanneke J van der Woude,Anne J Lexmond,Tineke van den Hoorn,Peter G M Mol,Finbarr P Leacy,Agnieszka Przybyszewska,Bruno Sepodes,Thomas Castelnovo","doi":"10.1183/13993003.01506-2025","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"126 1","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The European Medicines Agency's review of Kaftrio (elexacaftor-tezacaftor-ivacaftor): extending its use to all people with CF aged 2 years and older who do not have two class I CFTR variants.\",\"authors\":\"Catherine Drai,Hanneke J van der Woude,Anne J Lexmond,Tineke van den Hoorn,Peter G M Mol,Finbarr P Leacy,Agnieszka Przybyszewska,Bruno Sepodes,Thomas Castelnovo\",\"doi\":\"10.1183/13993003.01506-2025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12265,\"journal\":{\"name\":\"European Respiratory Journal\",\"volume\":\"126 1\",\"pages\":\"\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Respiratory Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.01506-2025\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/13993003.01506-2025","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
The European Medicines Agency's review of Kaftrio (elexacaftor-tezacaftor-ivacaftor): extending its use to all people with CF aged 2 years and older who do not have two class I CFTR variants.
期刊介绍:
The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.